A Phase 1 Study Evaluating the Safety, Tolerability, and Efficacy of BL-B01D1 in Patients with Metastatic or Unresectable Non-Small Cell Lung Cancer.
Contact Information for Access
- vanesa.gregorc@inoc.it
- chiara.lazzari@inoc.it
- alessio.polidori@inoc.it
- martina.danzero@inoc.it
- ufficio.trials@inoc.it
Phase
FASE I
Status
ATTIVO
Objective of the study
1. To evaluate the safety and tolerability of BL-B01D1 in patients with metastatic or unresectable non-small cell lung cancer (NSCLC) and other solid tumors (HER2-negative breast cancer, esophageal cancer, small cell lung cancer (SCLC), nasopharyngeal carcinoma (NPC), and head and neck squamous cell carcinoma (HNSCC)).
2. Determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and two or more recommended doses for expansion (RDE) of BL-B01D1 in metastatic NSCLC and other solid tumors (HER2- breast cancer, esophageal carcinoma, SCLC, NPC, and HNSCC).
Solid Tumors
ClinicalTrials.gov ID NCT05983432
Sponsor: SystImmune Inc.
https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2023-506539-14-00
Pathologies
Breast Cancer , Male urologic cancers (urological tumors)
Medication
BL-B01D1 (anti-EGFR and anti-HER3 antibody)
Who is eligible to participate in the study?
Patients who are 18 years of age or older and who meet the study’s eligibility criteria may participate in this study.
Patients with triple-negative breast cancer who have received prior chemotherapy and prior hormonal therapy, with or without targeted therapy
View the full study Back to search page